Menu Search
Equities

Teva Pharmaceutical Industries Ltd

TEVJF:PKC

Teva Pharmaceutical Industries Ltd

Actions
  • Price (USD)15.78
  • Today's Change0.00 / 0.00%
  • Shares traded108.00
  • 1 Year change+67.87%
  • Beta--
Data delayed at least 15 minutes, as of Nov 20 2024 13:04 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

  • Revenue in ILS (TTM)62.59bn
  • Net income in ILS-3.71bn
  • Incorporated1944
  • Employees35.00k
  • Location
    Teva Pharmaceutical Industries Ltd124 Dvora Hanevi'a St.TEL AVIV-YAFO 6944020IsraelISR
  • Phone+972 39148213
  • Fax+972 39234050
  • Websitehttps://www.tevapharm.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.